Literature DB >> 19553323

Virus entry via the alternative coreceptors CCR3 and FPRL1 differs by human immunodeficiency virus type 1 subtype.

R Nedellec1, M Coetzer, N Shimizu, H Hoshino, V R Polonis, L Morris, U E A Mårtensson, J Binley, J Overbaugh, D E Mosier.   

Abstract

Human immunodeficiency virus type 1 (HIV-1) infects target cells by binding to CD4 and a chemokine receptor, most commonly CCR5. CXCR4 is a frequent alternative coreceptor (CoR) in subtype B and D HIV-1 infection, but the importance of many other alternative CoRs remains elusive. We have analyzed HIV-1 envelope (Env) proteins from 66 individuals infected with the major subtypes of HIV-1 to determine if virus entry into highly permissive NP-2 cell lines expressing most known alternative CoRs differed by HIV-1 subtype. We also performed linear regression analysis to determine if virus entry via the major CoR CCR5 correlated with use of any alternative CoR and if this correlation differed by subtype. Virus pseudotyped with subtype B Env showed robust entry via CCR3 that was highly correlated with CCR5 entry efficiency. By contrast, viruses pseudotyped with subtype A and C Env proteins were able to use the recently described alternative CoR FPRL1 more efficiently than CCR3, and use of FPRL1 was correlated with CCR5 entry. Subtype D Env was unable to use either CCR3 or FPRL1 efficiently, a unique pattern of alternative CoR use. These results suggest that each subtype of circulating HIV-1 may be subject to somewhat different selective pressures for Env-mediated entry into target cells and suggest that CCR3 may be used as a surrogate CoR by subtype B while FPRL1 may be used as a surrogate CoR by subtypes A and C. These data may provide insight into development of resistance to CCR5-targeted entry inhibitors and alternative entry pathways for each HIV-1 subtype.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19553323      PMCID: PMC2738165          DOI: 10.1128/JVI.00780-09

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  81 in total

1.  Use of coreceptors other than CCR5 by non-syncytium-inducing adult and pediatric isolates of human immunodeficiency virus type 1 is rare in vitro.

Authors:  Y J Zhang; T Dragic; Y Cao; L Kostrikis; D S Kwon; D R Littman; V N KewalRamani; J P Moore
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

2.  The ability of HIV type 1 to use CCR-3 as a coreceptor is controlled by envelope V1/V2 sequences acting in conjunction with a CCR-5 tropic V3 loop.

Authors:  T M Ross; B R Cullen
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

3.  An orphan seven-transmembrane domain receptor expressed widely in the brain functions as a coreceptor for human immunodeficiency virus type 1 and simian immunodeficiency virus.

Authors:  A L Edinger; T L Hoffman; M Sharron; B Lee; Y Yi; W Choe; D L Kolson; B Mitrovic; Y Zhou; D Faulds; R G Collman; J Hesselgesser; R Horuk; R W Doms
Journal:  J Virol       Date:  1998-10       Impact factor: 5.103

4.  HIV type I envelope determinants for use of the CCR2b, CCR3, STRL33, and APJ coreceptors.

Authors:  T L Hoffman; E B Stephens; O Narayan; R W Doms
Journal:  Proc Natl Acad Sci U S A       Date:  1998-09-15       Impact factor: 11.205

5.  An orphan G protein-coupled receptor, GPR1, acts as a coreceptor to allow replication of human immunodeficiency virus types 1 and 2 in brain-derived cells.

Authors:  N Shimizu; Y Soda; K Kanbe; H Y Liu; A Jinno; T Kitamura; H Hoshino
Journal:  J Virol       Date:  1999-06       Impact factor: 5.103

6.  Establishment of a new system for determination of coreceptor usages of HIV based on the human glioma NP-2 cell line.

Authors:  Y Soda; N Shimizu; A Jinno; H Y Liu; K Kanbe; T Kitamura; H Hoshino
Journal:  Biochem Biophys Res Commun       Date:  1999-05-10       Impact factor: 3.575

7.  The orphan seven-transmembrane receptor apj supports the entry of primary T-cell-line-tropic and dualtropic human immunodeficiency virus type 1.

Authors:  H Choe; M Farzan; M Konkel; K Martin; Y Sun; L Marcon; M Cayabyab; M Berman; M E Dorf; N Gerard; C Gerard; J Sodroski
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

8.  Use of GPR1, GPR15, and STRL33 as coreceptors by diverse human immunodeficiency virus type 1 and simian immunodeficiency virus envelope proteins.

Authors:  A L Edinger; T L Hoffman; M Sharron; B Lee; B O'Dowd; R W Doms
Journal:  Virology       Date:  1998-09-30       Impact factor: 3.616

9.  Adaptation to promiscuous usage of CC and CXC-chemokine coreceptors in vivo correlates with HIV-1 disease progression.

Authors:  L Xiao; D L Rudolph; S M Owen; T J Spira; R B Lal
Journal:  AIDS       Date:  1998-09-10       Impact factor: 4.177

10.  Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1.

Authors:  L Zhang; T He; Y Huang; Z Chen; Y Guo; S Wu; K J Kunstman; R C Brown; J P Phair; A U Neumann; D D Ho; S M Wolinsky
Journal:  J Virol       Date:  1998-11       Impact factor: 5.103

View more
  24 in total

1.  Extreme genetic divergence is required for coreceptor switching in HIV-1 subtype C.

Authors:  Mia Coetzer; Rebecca Nedellec; Tonie Cilliers; Tammy Meyers; Lynn Morris; Donald E Mosier
Journal:  J Acquir Immune Defic Syndr       Date:  2011-01-01       Impact factor: 3.731

2.  In silico design of multi-target inhibitors for C-C chemokine receptors using substructural descriptors.

Authors:  Alejandro Speck-Planche; Valeria V Kleandrova
Journal:  Mol Divers       Date:  2011-10-22       Impact factor: 2.943

3.  Primary infection by a human immunodeficiency virus with atypical coreceptor tropism.

Authors:  Chunlai Jiang; Nicholas F Parrish; Craig B Wilen; Hui Li; Yue Chen; Jeffrey W Pavlicek; Anna Berg; Xiaozhi Lu; Hongshuo Song; John C Tilton; Jennifer M Pfaff; Elizabeth A Henning; Julie M Decker; M Anthony Moody; Mark S Drinker; Robert Schutte; Stephanie Freel; Georgia D Tomaras; Rebecca Nedellec; Donald E Mosier; Barton F Haynes; George M Shaw; Beatrice H Hahn; Robert W Doms; Feng Gao
Journal:  J Virol       Date:  2011-08-10       Impact factor: 5.103

4.  The HIV-1 gp41 ectodomain is cleaved by matriptase to produce a chemotactic peptide that acts through FPR2.

Authors:  Matthew P Wood; Amy L Cole; Colleen R Eade; Li-Mei Chen; Karl X Chai; Alexander M Cole
Journal:  Immunology       Date:  2014-07       Impact factor: 7.397

5.  Efficiency of CCR5 coreceptor utilization by the HIV quasispecies increases over time, but is not associated with disease progression.

Authors:  Andrew D Redd; Oliver Laeyendecker; Xiangrong Kong; Noah Kiwanuka; Tom Lutalo; Wei Huang; Ronald H Gray; Maria J Wawer; David Serwadda; Susan H Eshleman; Thomas C Quinn
Journal:  AIDS Res Hum Retroviruses       Date:  2011-08-05       Impact factor: 2.205

6.  Viremic control and viral coreceptor usage in two HIV-1-infected persons homozygous for CCR5 Δ32.

Authors:  Timothy J Henrich; Emily Hanhauser; Zixin Hu; Hans-Jürgen Stellbrink; Christian Noah; Jeffrey N Martin; Steven G Deeks; Daniel R Kuritzkes; Florencia Pereyra
Journal:  AIDS       Date:  2015-05-15       Impact factor: 4.177

7.  Variation in the biological properties of HIV-1 R5 envelopes: implications of envelope structure, transmission and pathogenesis.

Authors:  Maria José Duenas-Decamp; Paul J Peters; Alexander Repik; Thomas Musich; Maria Paz Gonzalez-Perez; Catherine Caron; Richard Brown; Jonathan Ball; Paul R Clapham
Journal:  Future Virol       Date:  2010-07       Impact factor: 1.831

8.  Comprehensive Characterization of the Transmitted/Founder env Genes From a Single MSM Cohort in China.

Authors:  Yue Chen; Ning Li; Tong Zhang; Xiaojie Huang; Fangping Cai; Nathan Vandergrift; Ruolei Xin; Zhefeng Meng; Xiaoyan Zhang; Chunlai Jiang; Xiaoning Xu; David C Montefiori; Feng Gao; Hao Wu
Journal:  J Acquir Immune Defic Syndr       Date:  2015-08-01       Impact factor: 3.731

9.  A rev1-vpu polymorphism unique to HIV-1 subtype A and C strains impairs envelope glycoprotein expression from rev-vpu-env cassettes and reduces virion infectivity in pseudotyping assays.

Authors:  Matthias H Kraus; Nicholas F Parrish; Katharina S Shaw; Julie M Decker; Brandon F Keele; Jesus F Salazar-Gonzalez; Truman Grayson; David T McPherson; Li-Hua Ping; Jeffrey A Anderson; Ronald Swanstrom; Carolyn Williamson; George M Shaw; Beatrice H Hahn
Journal:  Virology       Date:  2009-12-08       Impact factor: 3.616

Review 10.  Affinofile profiling: how efficiency of CD4/CCR5 usage impacts the biological and pathogenic phenotype of HIV.

Authors:  Kelechi Chikere; Tom Chou; Paul R Gorry; Benhur Lee
Journal:  Virology       Date:  2013-01-05       Impact factor: 3.616

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.